Treatment of inclusion body myositis: is low-dose intravenous immunoglobulin the solution?
| Autor: | Mike Recher, Adriano Fontana, Ulrike Sahrbacher, Börge Arndt, Urs C. Steiner, Juliane Bremer |
|---|---|
| Přispěvatelé: | University of Zurich, Recher, M |
| Jazyk: | angličtina |
| Rok vydání: | 2018 |
| Předmět: |
medicine.medical_specialty
2745 Rheumatology Immunology Drug Resistance 610 Medicine & health Azathioprine Disease 10263 Institute of Experimental Immunology Gastroenterology Myositis Inclusion Body Inflammatory myopathy Rheumatology Adrenal Cortex Hormones Internal medicine Humans Immunology and Allergy Medicine Muscle Skeletal Myositis Aged 2403 Immunology biology business.industry Low dose Immunoglobulins Intravenous medicine.disease Treatment Outcome 10033 Clinic for Immunology 2723 Immunology and Allergy biology.protein 570 Life sciences Female Inclusion body myositis Antibody business medicine.drug |
| Popis: | Inclusion body myositis (IBM), the most common inflammatory myopathy in the elderly, is often resistant to various forms of therapy. Placebo-controlled treatment trials with high dose intravenous immunoglobulins (IVIG) have shown disease amelioration in some but not all patients. Here, we present the informative case of a 70-year-old woman with diagnosed inclusion body myositis that showed progressive muscle weakness without treatment and following immuno-suppressive treatment with corticosteroids and azathioprine. A trial with low-dose intravenous immunoglobulins was started at that time. The patient responded rapidly to low dose IVIG treatment with amelioration of muscle strength and normalization of CK serum activities. Our results demonstrate that IBM patients may respond to low-dose IVIG treatment which has important clinical and economic consequences. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|